Drug Profile


Alternative Names: Coaxil; Stablon

Latest Information Update: 01 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Servier
  • Developer Servier; Vela Pharmaceuticals
  • Class Irritable bowel syndrome therapies; Small molecules; Thiazepines; Tricyclic antidepressants
  • Mechanism of Action Serotonin uptake stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anxiety disorders; Major depressive disorder
  • Market Withdrawal Alcoholism
  • Discontinued Asthma; Irritable bowel syndrome

Most Recent Events

  • 01 Jan 2016 Servier completes a phase III trial in Major depressive disorder (In the elderly) in Slovakia, Finland, Estonia, Bulgaria (PO) (EudraCT2012-005612-26)
  • 25 Oct 2006 Vela Pharmaceuticals has been acquired by Pharmos Corporation
  • 05 Feb 2004 Preclinical trials in Irritable bowel syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top